An interventional study of Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg) in Nasal Carriers of Staphylococcus Aureus, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-05.
Sponsored by Northwestern University · Not applicable, Interventional, and Treatment
Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.
273 studies on the registry are indexed under Staphylococcal Infections; 29 are open to participants now.
This study's enrollment of 216 is above the median of 120 across 177 interventional studies indexed under Staphylococcal Infections.
Browse Staphylococcal Infections studies →Northwestern University is the lead sponsor of 1,396 studies on the registry; 199 are open to participants now.
Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
Carrier Rate for Staphylococcus Aureus
Percentage of subjects with baseline culture positive for Staphylococcus aureus (via nasal swab)
Time frame: Baseline
MSSA Clearance Rate
Percentage of subjects with methicillin-sensitive S. aureus on Baseline culture who achieved clearance with treatment.
Time frame: 14 days
MRSA Clearance Rate
Percentage of subjects with methicillin-resistant S. aureus on Baseline culture who achieved clearance with treatment.
Time frame: 14 days
| Milestone | All Subjects |
|---|---|
| Started | 216 |
| Treated for positive baseline culture | 30 |
| Completed | 30 |
| Not completed | 186 |
Percentage of subjects with baseline culture positive for Staphylococcus aureus (via nasal swab)
| percentage of subjects | All Subjects |
|---|---|
| Carrier Rate for Staphylococcus Aureus | 20.8 |
Percentage of subjects with methicillin-sensitive S. aureus on Baseline culture who achieved clearance with treatment.
| percentage of subjects | MSSA |
|---|---|
| MSSA Clearance Rate | 57.1 |
Percentage of subjects with methicillin-resistant S. aureus on Baseline culture who achieved clearance with treatment.
| percentage of subjects | MRSA |
|---|---|
| MRSA Clearance Rate | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | — | 0/216 (0%) | 0/216 (0%) |
| Age, Categorical(Participants) | Treatment Group |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 30 |
| >=65 years | 0 |
| Age, Continuous(years) | Treatment Group |
|---|---|
| Mean | 39.3 ± 10.9 |
| Sex: Female, Male(Participants) | Treatment Group |
|---|---|
| Female | 21 |
| Male | 9 |
| Region of Enrollment(participants) | Treatment Group |
|---|---|
| United States | 30 |
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Northwestern University